Pyrazine Kinase Inhibitors for Selective Syk Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by Syk kinase activity, such as restenosis and inflammation, lack effective inhibitors that selectively target Syk kinase without affecting other kinases, and there is a need for compounds that can inhibit Syk kinase activity to treat various diseases including autoimmune and cardiovascular diseases.
Innovation Solution
Development of novel pyrazine compounds that act as selective inhibitors of Syk kinase, which can be used in pharmaceutical compositions to treat conditions like restenosis, inflammation, and autoimmune diseases by administering a therapeutically effective amount of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for Syk-mediated conditions, then general kinase inhibition occurs, but selectivity for Syk kinase is not achieved
Solution Approach 1:
The patent applies local quality by designing a pyrazine compound with specific substituent patterns at defined positions (R1, R2, R3, R4, R5, R6, R7, R8) to create selective interaction with Syk kinase binding site. The compound structure is optimized to match the specific spatial and chemical requirements of Syk kinase ATP-binding pocket, ensuring selective inhibition without affecting other kinase families.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the pyrazine core structure, including substituent types, positions, and configurations. By modifying these chemical parameters and testing their effect on Syk kinase inhibition selectivity, the inventors optimized the compound to achieve high selectivity for Syk over other kinases while maintaining therapeutic efficacy.
2Productivity
If non-selective kinase inhibitors are used, then broad kinase activity is inhibited, but therapeutic precision for Syk-mediated diseases is reduced
Solution Approach 1:
The pyrazine compound structure is designed with specific local chemical features (substituents at defined positions) that create precise molecular recognition with Syk kinase. This local quality optimization ensures the compound binds selectively to Syk's unique structural features, achieving both high target specificity and therapeutic efficacy for Syk-mediated diseases.
Solution Approach 2:
The pyrazine compound acts as an intermediary molecule that specifically mediates inhibition between the drug delivery system and Syk kinase. The compound's structured design allows it to selectively interface with Syk's active site, translating therapeutic intent into precise enzymatic inhibition without off-target effects on other kinases.
3Reliability
If selective Syk inhibitors are developed, then therapeutic precision improves, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the pyrazine compound into distinct functional segments (core pyrazine structure and substituent groups at specific positions). This segmentation allows systematic optimization of each segment's contribution to Syk selectivity, simplifying the development process while achieving high selective inhibition through modular structure-activity relationship analysis.
Data Source
AI summary
Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.